Department of Gastroenterology, Regional Institute of Gastroenterology and Hepatology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of Pathology, Regional Institute of Gastroenterology and Hepatology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Diagn Cytopathol. 2021 Mar;49(3):395-403. doi: 10.1002/dc.24669. Epub 2020 Nov 21.
BACKGROUND: Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) is important for the differential diagnosis of solid pancreatic lesions. Sample adequacy is related to the number of needle passes, and European guidelines recommend three to four needle passes with a standard EUS-FNA needle. We aimed to evaluate the optimal number of passes with standard EUS-FNA needles in solid pancreatic lesions. METHODS: Patients with solid pancreatic masses without cystic component >20% on computed tomography scan, and without biliary metallic stents, or coagulation problems were included prospectively. Standard 22G needles were used (maximum four passes); each sample was paraffin-embedded and analyzed separately. Final diagnosis was established by EUS-FNA, repeat EUS-FNA, surgery, or follow-up. RESULTS: Sixty-one of 65 patients were included. The final diagnoses were adenocarcinoma (n = 44, 72%), neuroendocrine tumor (NET) (n = 10, 16%), metastasis (n = 1, 4%) and nonmalignant lesion (n = 6, 10%). Immunohistochemical staining was possible in 17 cases. The diagnosis was established by the first pass in 62% of cases (n = 38), by the second in 15% (n = 9), by the third in 15% (n = 9), and by the fourth in 3% (n = 2). The diagnostic accuracy for all four passes compared to the first three passes was 95% vs 92% (P = .5). The contribution of the fourth pass was not different between adenocarcinoma and NET (2% vs 10%, respectively; P = .667). CONCLUSION: Three passes with standard EUS-FNA was optimal for a specific diagnosis of solid pancreatic masses, regardless of the histological type of the lesion.
背景:内镜超声引导下细针抽吸术(EUS-FNA)对于鉴别诊断实性胰腺病变很重要。样本充足度与针数有关,欧洲指南建议使用标准 EUS-FNA 针进行三到四次穿刺。我们旨在评估标准 EUS-FNA 针在实性胰腺病变中的最佳穿刺次数。
方法:前瞻性纳入 CT 扫描显示无囊性成分>20%的实性胰腺肿块且无胆道金属支架或凝血问题的患者。使用标准 22G 针(最多穿刺四次);每个样本单独包埋和分析。最终诊断通过 EUS-FNA、重复 EUS-FNA、手术或随访确定。
结果:65 例患者中 61 例入选。最终诊断为腺癌(n = 44,72%)、神经内分泌肿瘤(NET)(n = 10,16%)、转移(n = 1,4%)和非恶性病变(n = 6,10%)。17 例可进行免疫组织化学染色。62%(n = 38)的病例在第一次穿刺时即可确立诊断,15%(n = 9)的病例在第二次穿刺时,15%(n = 9)的病例在第三次穿刺时,3%(n = 2)的病例在第四次穿刺时确立诊断。与前三次穿刺相比,四次穿刺的诊断准确率为 95%对 92%(P =.5)。腺癌和 NET 中第四次穿刺的贡献无差异(分别为 2%对 10%;P =.667)。
结论:标准 EUS-FNA 三次穿刺对实性胰腺肿块的特定诊断是最佳的,与病变的组织学类型无关。
World J Gastroenterol. 2016-10-21
Diagnostics (Basel). 2022-3-19